<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01045096</url>
  </required_header>
  <id_info>
    <org_study_id>T-P107-174</org_study_id>
    <secondary_id>U1111-1112-1684</secondary_id>
    <nct_id>NCT01045096</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, Parallel Design, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole Delayed Release Capsules in Pediatric Subjects Ages 1 to 11 Years Old With Symptomatic Gastroesophageal Reflux Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetics and safety of dexlansoprazole,
      once daily (QD), in pediatric subjects with symptomatic Gastroesophageal Reflux Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastroesophageal Reflux Disease (GERD) is a condition of several causes resulting in the
      backward flow of gastric contents into the esophagus through the lower esophageal sphincter.
      The prevalence of GERD in the pediatric population is increasingly becoming recognized and
      documented. It is a disease that may persist through adulthood, with symptoms in older
      children and adolescents similar to those seen in adults.

      Younger children generally present with extra-esophageal manifestations, regurgitation, and
      epigastric pain, while older children and adolescents typically present with adult-type GERD
      symptoms of heartburn and regurgitation. Treatment for GERD is aimed at improving symptoms
      and healing esophageal inflammation.

      Takeda Global Research &amp; Development Center, Inc. (TGRD) developed dexlansoprazole delayed
      release capsules as a new therapy for treating acid related disorders including symptomatic
      non-erosive GERD, healing of erosive esophagitis (EE) and maintenance of healed EE.

      Dexlansoprazole delayed release capsules have not been studied in subjects younger than 12
      years of age. This study is designed to evaluate the safety of dexlansoprazole delayed
      release capsules in the pediatric population (1 to 11 years old) and to determine if the PK
      profile of dexlansoprazole in subjects 1 to 11 years of age is similar to that in adults
      given a similar dose.

      Subjects who satisfy the screening evaluation and Inclusion/Exclusion Criteria may be
      enrolled in the study. Eligible subjects will be assigned to one of three treatment groups.
      Attempts will be made to enroll an equal number of male and female subjects in each treatment
      group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Reach the Peak Plasma Concentration (Tmax)</measure>
    <time_frame>Day 7 after 7 days of dosing with dexlansoprazole delayed release capsules.</time_frame>
    <description>Time to reach the maximum plasma concentration (Cmax) of Dexlansoprazole, equal to time (hours) to Cmax, as observed on Day 7. Pharmacokinetic parameters were derived using noncompartmental methods from the plasma concentrations of dexlansoprazole.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Day 7 after 7 days of dosing with dexlansoprazole delayed release capsules.</time_frame>
    <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Pharmacokinetic parameters were derived using noncompartmental methods from the plasma concentrations of dexlansoprazole.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUC(0-tlqc))</measure>
    <time_frame>Day 7 after 7 days of dosing with dexlansoprazole delayed release capsules.</time_frame>
    <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (tlqc), calculated using the linear trapezoidal rule. Pharmacokinetic parameters were derived using noncompartmental methods from the plasma concentrations of dexlansoprazole.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to 24 Hours Post-dose (AUC(0-24))</measure>
    <time_frame>Day 7 after 7 days of dosing with dexlansoprazole delayed release capsules.</time_frame>
    <description>AUC(0-24) is measure of area under the curve over the dosing interval (tau), where tau is the length of the dosing interval (24 hours), calculated using the linear trapezoidal rule. Pharmacokinetic parameters were derived using noncompartmental methods from the plasma concentrations of dexlansoprazole.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>Dexlansoprazole 15 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexlansoprazole 30 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexlansoprazole 60 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexlansoprazole</intervention_name>
    <description>Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.</description>
    <arm_group_label>Dexlansoprazole 15 mg QD</arm_group_label>
    <other_name>Kapidex</other_name>
    <other_name>TAK-390MR</other_name>
    <other_name>Dexilant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexlansoprazole</intervention_name>
    <description>Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days</description>
    <arm_group_label>Dexlansoprazole 30 mg QD</arm_group_label>
    <other_name>Kapidex</other_name>
    <other_name>TAK-390MR</other_name>
    <other_name>Dexilant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexlansoprazole</intervention_name>
    <description>Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days</description>
    <arm_group_label>Dexlansoprazole 60 mg QD</arm_group_label>
    <other_name>Kapidex</other_name>
    <other_name>TAK-390MR</other_name>
    <other_name>Dexilant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have a body weight within the 5th through 95th percentile by age, inclusive, as
             determined by the National Center for Health Statistics .

          -  Females of childbearing potential must not be nursing, must have a negative serum
             pregnancy test at the Screening Visit and on Day -1, and if sexually active agree to
             routinely use adequate contraception from Screening and throughout the duration of the
             study.

          -  Subjects who take prescription or non-prescription proton pump inhibitors (PPI),
             histamine receptor antagonists (except cimetidine), sucralfate, or antacids on a
             regular or as required basis must agree to discontinue usage on Day -1 and agree to
             discontinue use throughout the study.

          -  Must have a history of GERD symptoms for at least 2 months prior to Screening or is
             currently symptomatic, as determined by the investigator.

          -  Must be able to swallow study drug capsule or must be able to ingest study drug
             granules sprinkled on 1 tablespoon of applesauce.

        Exclusion Criteria:

          -  Has evidence of current cardiovascular, central nervous system, pulmonary, endocrine
             disease, hepatic, hematopoietic, renal, or metabolic dysfunction, serious allergy,
             asthma, or allergic skin rash.

          -  Has a known hypersensitivity to any PPI or any component of the formulation of
             dexlansoprazole capsules.

          -  Is taking any other prescription (except birth control) or nonprescription medication
             (including cimetidine), vitamins, or dietary supplements within 10 days prior to Day
             1, or has taken herbal over-the-counter medications within 28 days prior to Day 1.

          -  Has a positive test result for hepatitis B surface antigen or hepatitis C virus
             antibody.

          -  Has donated or lost greater than 10% of the total blood volume, undergone
             plasmapheresis, or has had a transfusion of any blood product within 90 days prior to
             the first dose of study drug.

          -  Has a history of alcohol abuse or illegal drug use or drug abuse in the past, or tests
             positive for alcohol or drugs of abuse at the initial Screening Visit or Day -1 or is
             unwilling to agree to abstain from alcohol and drugs throughout the study.

          -  Has used a product containing nicotine within 90 days prior to the first dose of study
             drug or has a positive cotinine screen at the initial Screening Visit or Day -1 or is
             unwilling to agree to abstain throughout the study.

          -  Is determined to be a Cytochrome P450 2C19 poor metabolizer (ie, genotyped homozygous
             non-wild-type).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami Garden</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://general.takedapharm.com/content/file/pi.pdf?applicationcode=9efb34b3-fb69-4190-a2be-a90b8cb94e25&amp;filetypecode=DEXILANTPI</url>
    <description>Dexilant Package Insert</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2010</study_first_submitted>
  <study_first_submitted_qc>January 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2010</study_first_posted>
  <results_first_submitted>January 30, 2012</results_first_submitted>
  <results_first_submitted_qc>March 8, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 5, 2012</results_first_posted>
  <last_update_submitted>March 8, 2012</last_update_submitted>
  <last_update_submitted_qc>March 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroesophageal Reflux</keyword>
  <keyword>Erosive Esophagitis</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in this study at 3 investigative sites in the United States from 04 March 2010 to 09 February 2011.</recruitment_details>
      <pre_assignment_details>36 participants with gastroesophageal reflux disease were assigned to 1 of 3 once daily (QD) treatment regimens (15 mg, 30 mg or 60 mg dexlansoprazole) based on baseline body weight.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dexlansoprazole 15 mg QD</title>
          <description>Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.</description>
        </group>
        <group group_id="P2">
          <title>Dexlansoprazole 30 mg QD</title>
          <description>Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days</description>
        </group>
        <group group_id="P3">
          <title>Dexlansoprazole 60 mg QD</title>
          <description>Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pharmacokinetic Set</title>
              <participants_list>
                <participants group_id="P1" count="9">All patients with at least one estimable PK parameter for dexlansoprazole on Day 7.</participants>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexlansoprazole 15 mg QD</title>
          <description>Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.</description>
        </group>
        <group group_id="B2">
          <title>Dexlansoprazole 30 mg QD</title>
          <description>Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days</description>
        </group>
        <group group_id="B3">
          <title>Dexlansoprazole 60 mg QD</title>
          <description>Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.3" spread="1.97"/>
                    <measurement group_id="B2" value="7.8" spread="2.89"/>
                    <measurement group_id="B3" value="10.2" spread="0.72"/>
                    <measurement group_id="B4" value="7.1" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiracial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean height</title>
          <description>Height for one patient in the Dexlansoprazole 15 mg group was incorrectly reported (as 38 cm instead of 96.52 cm) and is included in the mean height reported here. The mean height excluding this patient is 97.45 cm.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.5" spread="24.16"/>
                    <measurement group_id="B2" value="131.9" spread="18.80"/>
                    <measurement group_id="B3" value="146.3" spread="8.73"/>
                    <measurement group_id="B4" value="123.6" spread="29.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Overall Mean Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.7" spread="5.43"/>
                    <measurement group_id="B2" value="29.7" spread="11.86"/>
                    <measurement group_id="B3" value="41.0" spread="8.50"/>
                    <measurement group_id="B4" value="28.8" spread="13.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Participants per Weight Group</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>8.6 kg - &lt; 12.7 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12.7 kg - &lt; 25.4 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 25.4 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Weight per Weight Group</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>8.6 kg - &lt; 12.7 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.1" spread="1.05"/>
                    <measurement group_id="B2" value="NA">There were no participants in this group</measurement>
                    <measurement group_id="B3" value="NA">There were no participants in this group</measurement>
                    <measurement group_id="B4" value="11.1" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12.7 kg - &lt; 25.4 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.0" spread="4.76"/>
                    <measurement group_id="B2" value="20.3" spread="3.67"/>
                    <measurement group_id="B3" value="NA">There were no participants in this group</measurement>
                    <measurement group_id="B4" value="19.6" spread="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 25.4 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There were no participants in this group</measurement>
                    <measurement group_id="B2" value="39.1" spread="9.19"/>
                    <measurement group_id="B3" value="41.0" spread="8.50"/>
                    <measurement group_id="B4" value="40.3" spread="8.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Height for one patient in the Dexlansoprazole 15 mg group was incorrectly reported (as 38 cm instead of 96.52 cm) and is included in the mean BMI reported here. The mean BMI excluding this patient is 16.52 kg/m^2.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.3" spread="20.08"/>
                    <measurement group_id="B2" value="16.4" spread="3.09"/>
                    <measurement group_id="B3" value="19.0" spread="2.56"/>
                    <measurement group_id="B4" value="19.2" spread="11.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach the Peak Plasma Concentration (Tmax)</title>
        <description>Time to reach the maximum plasma concentration (Cmax) of Dexlansoprazole, equal to time (hours) to Cmax, as observed on Day 7. Pharmacokinetic parameters were derived using noncompartmental methods from the plasma concentrations of dexlansoprazole.</description>
        <time_frame>Day 7 after 7 days of dosing with dexlansoprazole delayed release capsules.</time_frame>
        <population>Pharmacokinetic (PK) set included all participants with at least one estimable PK parameter for dexlansoprazole on Day 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexlansoprazole 15 mg QD</title>
            <description>Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Dexlansoprazole 30 mg QD</title>
            <description>Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days</description>
          </group>
          <group group_id="O3">
            <title>Dexlansoprazole 60 mg QD</title>
            <description>Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach the Peak Plasma Concentration (Tmax)</title>
          <description>Time to reach the maximum plasma concentration (Cmax) of Dexlansoprazole, equal to time (hours) to Cmax, as observed on Day 7. Pharmacokinetic parameters were derived using noncompartmental methods from the plasma concentrations of dexlansoprazole.</description>
          <population>Pharmacokinetic (PK) set included all participants with at least one estimable PK parameter for dexlansoprazole on Day 7.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="3.18"/>
                    <measurement group_id="O2" value="4.1" spread="2.34"/>
                    <measurement group_id="O3" value="4.1" spread="3.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sample size of 12 participants per dose group, along with the intense PK sampling in each regimen was needed for characterization of the PK profile. An analysis of variance with covariates (ANCOVA) model with weight as a covariate and regimen as a factor were fitted to Tmax. Pairwise comparisons between regimens were conducted.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.809</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Dose-normalized Peak Plasma Concentration (Cmax/Dose)</title>
        <description>Maximum observed plasma concentration (the peak plasma concentration of a drug after administration), normalized by dose. Pharmacokinetic parameters were derived using noncompartmental methods from the plasma concentrations of dexlansoprazole.</description>
        <time_frame>Day 7 after 7 days of dosing with dexlansoprazole delayed release capsules.</time_frame>
        <population>Pharmacokinetic set included all participants with at least one estimable PK parameter for dexlansoprazole on Day 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexlansoprazole 15 mg QD</title>
            <description>Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Dexlansoprazole 30 mg QD</title>
            <description>Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days</description>
          </group>
          <group group_id="O3">
            <title>Dexlansoprazole 60 mg QD</title>
            <description>Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-normalized Peak Plasma Concentration (Cmax/Dose)</title>
          <description>Maximum observed plasma concentration (the peak plasma concentration of a drug after administration), normalized by dose. Pharmacokinetic parameters were derived using noncompartmental methods from the plasma concentrations of dexlansoprazole.</description>
          <population>Pharmacokinetic set included all participants with at least one estimable PK parameter for dexlansoprazole on Day 7.</population>
          <units>ng/mL/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" spread="15.02"/>
                    <measurement group_id="O2" value="33.5" spread="24.94"/>
                    <measurement group_id="O3" value="16.1" spread="8.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size of 12 participants per dose group, along with the intense PK sampling in each regimen was needed for characterization of the PK profile. An ANCOVA model with weight as a covariate and regimen as a factor were fitted to dose-normalized Cmax. Pairwise comparisons between regimens were conducted.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Dose Proportionality Point Estimate</param_type>
            <param_value>1.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.660</ci_lower_limit>
            <ci_upper_limit>2.183</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sample size of 12 participants per dose group, along with the intense PK sampling in each regimen was needed for characterization of the PK profile. An ANCOVA model with weight as a covariate and regimen as a factor were fitted to dose-normalized Cmax. Pairwise comparisons between regimens were conducted.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Dose proportionality Point Estimate</param_type>
            <param_value>1.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.463</ci_lower_limit>
            <ci_upper_limit>2.427</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sample size of 12 participants per dose group, along with the intense PK sampling in each regimen was needed for characterization of the PK profile. An ANCOVA model with weight as a covariate and regimen as a factor were fitted to dose-normalized Cmax. Pairwise comparisons between regimens were conducted.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Dose Proportionality Point Estimate</param_type>
            <param_value>0.88</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.493</ci_lower_limit>
            <ci_upper_limit>1.579</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Dose-normalized Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUC(0-tlqc)/Dose)</title>
        <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (tlqc), calculated using the linear trapezoidal rule, and normalized by dose. Pharmacokinetic parameters were derived using noncompartmental methods from the plasma concentrations of dexlansoprazole.</description>
        <time_frame>Day 7 after 7 days of dosing with dexlansoprazole delayed release capsules.</time_frame>
        <population>Pharmacokinetic set included all participants with at least one estimable PK parameter for dexlansoprazole on Day 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexlansoprazole 15 mg QD</title>
            <description>Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Dexlansoprazole 30 mg QD</title>
            <description>Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days</description>
          </group>
          <group group_id="O3">
            <title>Dexlansoprazole 60 mg QD</title>
            <description>Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-normalized Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUC(0-tlqc)/Dose)</title>
          <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (tlqc), calculated using the linear trapezoidal rule, and normalized by dose. Pharmacokinetic parameters were derived using noncompartmental methods from the plasma concentrations of dexlansoprazole.</description>
          <population>Pharmacokinetic set included all participants with at least one estimable PK parameter for dexlansoprazole on Day 7.</population>
          <units>ng*hr/mL/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" spread="42.1"/>
                    <measurement group_id="O2" value="96" spread="55.6"/>
                    <measurement group_id="O3" value="62" spread="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size of 12 participants per dose group, along with the intense PK sampling in each regimen was needed for characterization of the PK profile. An ANCOVA model with weight as a covariate and regimen as a factor were fitted to dose-normalized AUC[0-tlqc]. Pairwise comparisons between regimens were conducted.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Dose Proportionality Point Estimate</param_type>
            <param_value>1.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.693</ci_lower_limit>
            <ci_upper_limit>1.848</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sample size of 12 participants per dose group, along with the intense PK sampling in each regimen was needed for characterization of the PK profile. An ANCOVA model with weight as a covariate and regimen as a factor were fitted to dose-normalized AUC[0-tlqc]. Pairwise comparisons between regimens were conducted.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Dose Proportionality Point Estimate</param_type>
            <param_value>1.15</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.584</ci_lower_limit>
            <ci_upper_limit>2.276</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sample size of 12 participants per dose group, along with the intense PK sampling in each regimen was needed for characterization of the PK profile. An ANCOVA model with weight as a covariate and regimen as a factor were fitted to dose-normalized AUC[0-tlqc]. Pairwise comparisons between regimens were conducted.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Dose Proportionality Point Estimate</param_type>
            <param_value>1.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.632</ci_lower_limit>
            <ci_upper_limit>1.642</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Dose-normalized Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to 24 Hours Post-dose (AUC(0-24)/Dose)</title>
        <description>AUC(0-24) is measure of area under the curve over the dosing interval (tau), where tau is the length of the dosing interval (24 hours), calculated using the linear trapezoidal rule and normalized by dose. Pharmacokinetic parameters were derived using noncompartmental methods from the plasma concentrations of dexlansoprazole.</description>
        <time_frame>Day 7 after 7 days of dosing with dexlansoprazole delayed release capsules.</time_frame>
        <population>Pharmacokinetic set included all participants with at least one estimable PK parameter for dexlansoprazole on Day 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexlansoprazole 15 mg QD</title>
            <description>Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Dexlansoprazole 30 mg QD</title>
            <description>Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days</description>
          </group>
          <group group_id="O3">
            <title>Dexlansoprazole 60 mg QD</title>
            <description>Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-normalized Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to 24 Hours Post-dose (AUC(0-24)/Dose)</title>
          <description>AUC(0-24) is measure of area under the curve over the dosing interval (tau), where tau is the length of the dosing interval (24 hours), calculated using the linear trapezoidal rule and normalized by dose. Pharmacokinetic parameters were derived using noncompartmental methods from the plasma concentrations of dexlansoprazole.</description>
          <population>Pharmacokinetic set included all participants with at least one estimable PK parameter for dexlansoprazole on Day 7.</population>
          <units>ng*hr/mL/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.2" spread="37.58"/>
                    <measurement group_id="O2" value="87.6" spread="46.11"/>
                    <measurement group_id="O3" value="55.5" spread="31.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size of 12 participants per dose group, along with the intense PK sampling in each regimen was needed for characterization of the PK profile. An ANCOVA model with weight as a covariate and regimen as a factor were fitted to dose-normalized AUC[0-24]. Pairwise comparisons between regimens were conducted.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Dose Proportionality Point Estimate</param_type>
            <param_value>1.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.692</ci_lower_limit>
            <ci_upper_limit>1.636</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sample size of 12 participants per dose group, along with the intense PK sampling in each regimen was needed for characterization of the PK profile. An ANCOVA model with weight as a covariate and regimen as a factor were fitted to dose-normalized AUC[0-24]. Pairwise comparisons between regimens were conducted.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Dose Proportionality Point Estimate</param_type>
            <param_value>1.26</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.691</ci_lower_limit>
            <ci_upper_limit>2.314</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sample size of 12 participants per dose group, along with the intense PK sampling in each regimen was needed for characterization of the PK profile. An ANCOVA model with weight as a covariate and regimen as a factor were fitted to dose-normalized AUC[0-24]. Pairwise comparisons between regimens were conducted.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Dose Proportionality Point Estimate</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.777</ci_lower_limit>
            <ci_upper_limit>1.817</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Peak Plasma Concentration (Cmax)</title>
        <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Pharmacokinetic parameters were derived using noncompartmental methods from the plasma concentrations of dexlansoprazole.</description>
        <time_frame>Day 7 after 7 days of dosing with dexlansoprazole delayed release capsules.</time_frame>
        <population>Pharmacokinetic set included all participants with at least one estimable PK parameter for dexlansoprazole on Day 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexlansoprazole 15 mg QD</title>
            <description>Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Dexlansoprazole 30 mg QD</title>
            <description>Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days</description>
          </group>
          <group group_id="O3">
            <title>Dexlansoprazole 60 mg QD</title>
            <description>Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Peak Plasma Concentration (Cmax)</title>
          <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Pharmacokinetic parameters were derived using noncompartmental methods from the plasma concentrations of dexlansoprazole.</description>
          <population>Pharmacokinetic set included all participants with at least one estimable PK parameter for dexlansoprazole on Day 7.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="559" spread="225.3"/>
                    <measurement group_id="O2" value="1005" spread="748.1"/>
                    <measurement group_id="O3" value="964" spread="519.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUC(0-tlqc))</title>
        <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (tlqc), calculated using the linear trapezoidal rule. Pharmacokinetic parameters were derived using noncompartmental methods from the plasma concentrations of dexlansoprazole.</description>
        <time_frame>Day 7 after 7 days of dosing with dexlansoprazole delayed release capsules.</time_frame>
        <population>Pharmacokinetic set included all participants with at least one estimable PK parameter for dexlansoprazole on Day 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexlansoprazole 15 mg QD</title>
            <description>Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Dexlansoprazole 30 mg QD</title>
            <description>Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days</description>
          </group>
          <group group_id="O3">
            <title>Dexlansoprazole 60 mg QD</title>
            <description>Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUC(0-tlqc))</title>
          <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (tlqc), calculated using the linear trapezoidal rule. Pharmacokinetic parameters were derived using noncompartmental methods from the plasma concentrations of dexlansoprazole.</description>
          <population>Pharmacokinetic set included all participants with at least one estimable PK parameter for dexlansoprazole on Day 7.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1914" spread="631.8"/>
                    <measurement group_id="O2" value="2892" spread="1668.6"/>
                    <measurement group_id="O3" value="3747" spread="2795.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to 24 Hours Post-dose (AUC(0-24))</title>
        <description>AUC(0-24) is measure of area under the curve over the dosing interval (tau), where tau is the length of the dosing interval (24 hours), calculated using the linear trapezoidal rule. Pharmacokinetic parameters were derived using noncompartmental methods from the plasma concentrations of dexlansoprazole.</description>
        <time_frame>Day 7 after 7 days of dosing with dexlansoprazole delayed release capsules.</time_frame>
        <population>Pharmacokinetic set included all participants with at least one estimable PK parameter for dexlansoprazole on Day 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexlansoprazole 15 mg QD</title>
            <description>Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Dexlansoprazole 30 mg QD</title>
            <description>Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days</description>
          </group>
          <group group_id="O3">
            <title>Dexlansoprazole 60 mg QD</title>
            <description>Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to 24 Hours Post-dose (AUC(0-24))</title>
          <description>AUC(0-24) is measure of area under the curve over the dosing interval (tau), where tau is the length of the dosing interval (24 hours), calculated using the linear trapezoidal rule. Pharmacokinetic parameters were derived using noncompartmental methods from the plasma concentrations of dexlansoprazole.</description>
          <population>Pharmacokinetic set included all participants with at least one estimable PK parameter for dexlansoprazole on Day 7.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2149" spread="563.7"/>
                    <measurement group_id="O2" value="2628" spread="1383.2"/>
                    <measurement group_id="O3" value="3330" spread="1883.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events with an onset that occurred after receiving study drug and within 30 days after the last dose of study drug.</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dexlansoprazole 15 mg QD</title>
          <description>Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Dexlansoprazole 30 mg QD</title>
          <description>Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days</description>
        </group>
        <group group_id="E3">
          <title>Dexlansoprazole 60 mg QD</title>
          <description>Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights therefrom or any data, information or materials obtained or generated in the performance of it’s obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. VP, Clinical Science</name_or_title>
      <organization>Takeda Global Research and Development Center, Inc.</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

